SCHEMBL5423201

SCHEMBL5423201

CCCCCCCOc1ccc(N(C(=O)c2cc(C)on2)c2nc(-c3nc4ccccc4s3)cs2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
RXFP1 Q9HBX9 1/20 0.43
ATP4A P20648 9/20 0.43
ATP4B P51164 9/20 0.43
MGLL Q99685 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPC1 O15118 4/20 0.36
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
SMPD1 P17405 1/20 0.35
CYP1A2 P05177 1/20 0.35
NFKB1 P19838 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14409898 1.00 MAPT (0.43) MAPTRXFP1ATP4AATP4BMGLL
SCHEMBL5431283 0.86 THRA (0.35) MAPTRXFP1ATP4AATP4BMGLL
SCHEMBL4720919 0.83 TDP1 (0.38) MAPTRXFP1ATP4AATP4BTDP1
SCHEMBL5427017 0.83 TDP1 (0.38) MAPTRXFP1ATP4AATP4BTDP1
SCHEMBL5428319 0.82 MAPT (0.47) MAPTRXFP1ATP4AATP4BNPC1
SCHEMBL9101339 0.77 NPC1 (0.36) MAPTATP4AATP4BNPC1ALDH1A1
SCHEMBL14409900 0.70 THRA (0.36) MAPTNPC1ALDH1A1RAB9ATP53
SCHEMBL5433977 0.70 NPC1 (0.38) MAPTRXFP1NPC1RAB9ASMN1; SMN2
SCHEMBL4656451 0.70 NPC1 (0.38) MAPTATP4AATP4BTDP1NPC1
SCHEMBL206547 0.69 ATP4A (0.52) MAPTRXFP1ATP4AATP4BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2460800-A1 Substituted aminothiazole derivatives with anti-HCV activity Achillion Pharmaceuticals, Inc. (US) 2012-06-06 EP claimed
US-20070213301-A1 Substituted Aminothiazole Derivatives With Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2007-09-13 US claimed
EP-2460800-A1 Substituted aminothiazole derivatives with anti-HCV activity Achillion Pharmaceuticals, Inc. (US) 2012-06-06 EP disclosed
US-20070213301-A1 Substituted Aminothiazole Derivatives With Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed
US-20070213301-A1 Substituted Aminothiazole Derivatives With Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed
US-20070213301-A1 Substituted Aminothiazole Derivatives With Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213301-A1 Substituted Aminothiazole Derivatives With Anti-HCV Activity EIF2AK2, BCAT1, IL4I1 MAPT 3967/4885RXFP1 2908/4885ATP4A 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.